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Background: Omalizumab has demonstrated clinical beneﬁts in children with moderate to severe allergic
asthma. However, no studies have been performed in Japanese asthmatic children. The aim of this study
was to evaluate the efﬁcacy including free IgE suppression and safety of omalizumab in Japanese children
with severe allergic asthma. The primary objective was to examine whether omalizumab decreases
serum free IgE levels to less than 25 ng/ml (target level of suppression).
Methods: Thirty-eight Japanese children (6e15 years) with uncontrolled severe allergic asthma despite
inhaled corticosteroids (>200 mg/day ﬂuticasone propionate or equivalent) and two or more controller
therapies received add-on treatment with omalizumab in a 24-week, multicenter, uncontrolled, open-
label study.
Results: The geometric mean serum free IgE level at 24 weeks was 15.6 ng/mL. Compared with baseline,
total asthma symptom scores, daily activity scores and nocturnal sleep scores at 24 weeks were signif-
icantly improved. The rates of asthma exacerbation and hospitalization due to asthma were reduced by
69.2% and 78.2%, respectively (p < 0.001), versus baseline. Quality-of-life scores were also signiﬁcantly
improved (p < 0.001). In addition, 11 (28.9%) patients reduced the dose of any asthma controller med-
ications. Thirty-six (94.7%) patients experienced at least one adverse event during the treatment period.
All adverse events were mild or moderate in severity and no new safety concerns were detected. No
patients discontinued the study.
Conclusions: In Japanese children with severe allergic asthma, omalizumab decreased free IgE levels to
less than 25 ng/mL. Omalizumab improved asthma control and was well-tolerated, as well.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Fukuoka National Hospital, 4-39-1 Yakatabaru, Minami-Ku, Fukuoka 811-1394, Japan.
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Asthma is one of the most common chronic diseases in child-
hood. In Japan, as well as in Western countries, the prevalence of
pediatric asthma is increasing: between 1982 and 2002, it
increased from 3.2% to 6.5%, representing a two-fold increase in just
20 years.1 Asthma in children is often poorly controlled, usually as a
result of undertreatment with controller medications; however,
some children have poor asthma control even with the highest
level of controller medications.2,3
Uncontrolled severe asthma results in a high risk of asthma
exacerbations and impaired quality of life.4 In particular, asthma
exacerbations are associated with decline in lung function,5 hos-
pital admissions and emergency room (ER) visits,6 and time lost
from work and school.7 They are frequently treated with systemic
(oral or intravenous [IV]) corticosteroids, which, if used in multiple
bursts over a period of years, can result in serious side effects such
as a reduction in bone mineral accretion and an increased risk of
osteopenia.8
The majority of children with asthma are atopic, and pediatric
patients with severe asthma have higher mean immunoglobulin E
(IgE) levels than those with moderate or mild asthma,9 providing a
particularly strong rationale for investigating anti-IgE therapy in
this population.
Omalizumab is a humanized monoclonal anti-IgE antibody that
binds IgE, rapidly suppressing free IgE concentrations; it prevents
IgE from interacting with high-afﬁnity IgE receptors on mast cells
and basophils, thereby interrupting the allergic cascade.10,11 Oma-
lizumab is approved for the treatment of adults and adolescents
(12 years) with moderate-to-severe (USA) or severe (EU) allergic
(IgE-mediated) asthma,12,13 and also for the treatment of adults
with severe allergic asthma in Japan.14 In the EU, the indication has
recently been extended to include children (6e<12 years) with
severe allergic asthma. In a randomized, double-blind, placebo-
controlled study in children (6e<12 years) with moderate-to-
severe allergic asthma, omalizumab signiﬁcantly reduced asthma
exacerbations compared with placebo.15,16
In the current study, the efﬁcacy including free IgE suppression
and safety of omalizumab in Japanese children aged 6e15 years
with uncontrolled severe persistent allergic asthma were investi-
gated for the ﬁrst time, to conﬁrm whether the outcome of treat-
ment in a Japanese/Asian population is consistent with ﬁndings in
previously studied populations.
Methods
Participants
Eligible patients were aged 6e15 years with a diagnosis of se-
vere persistent allergic asthma according to the Japanese pediatric
guideline for the treatment and management of asthma (JPGL)
2008.17 All patients had uncontrolled asthma despite receiving
inhaled corticosteroids (ICS) (>200 mg/day ﬂuticasone propionate
[FP] dry powder inhaler [or equivalent]) and two or more controller
medications (leukotriene receptor antagonist [LTRA], long-acting
b2-agonist [LABA], theophylline, sodium cromoglycate, and oral
corticosteroid), consistent with step 4 treatment (i.e. the mostintensive treatment step) of the JPGL 2008. ‘Uncontrolled’ was
deﬁned as meeting one of the following criteria during the
screening period: (1) asthma symptoms every day; (2) night-time
symptoms in 2 out of the last 14 days; (3) limitation of daily ac-
tivities in 2 out of the last 14 days.
In addition, patients had to have a history of two or more
documented asthma exacerbations requiring treatment with a
doubling of the maintenance ICS dose for at least 3 days and/or
systemic (oral or IV) corticosteroids; one of these had to have
occurred in the previous 12 months.
Patients were also required to have IgE sensitization to one of
the perennial aeroallergens, demonstrate at least an increase of 12%
in forced expiratory volume in one second (FEV1) within 30 min of
taking a short-acting b2-agonist (SABA), and have serum total IgE
levels of 30e1300 IU/mL and body weights of 20e150 kg to allow
optimal dosing of omalizumab.
Patients were excluded if they had: (1) active lung disease, other
than allergic asthma, that could potentially interfere with the
outcome; (2) a history of food or drug-related severe anaphylactoid
or anaphylactic reactions; (3) a positive skin test to omalizumab at
screening; (4) platelet level  100,000/mL (100  109/L) at
screening; or (5) a serious medical condition (e.g. cancer, hepatic
failure, renal failure).
Study design
This was a multicenter, uncontrolled, open-label study, con-
ducted at 17 centers in Japan, with a 2-week screening period, a 24-
week treatment period (consisting of a 16-week ﬁxed phase and an
8-week adjustable phase), and a follow-up investigation at 16
weeks after ﬁnal dosing.
Omalizumab 75e375 mg was administered every 2 or 4 weeks
by subcutaneous injection, with the dose being selected from a
standard dosing table (Fig. 1)15,18,19 according to baseline serum
total IgE level and bodyweight.
The doses of ICS and other controller medications for asthma
were kept constant for 4 weeks before the screening period, and
were maintained during the screening period and the ﬁxed phase
of the treatment period (unless adjustment was required for an
asthma exacerbation). During the ﬁrst 4 weeks of the adjustable
phase of the treatment period, doses could be adjusted downward
according to the JPGL 2008 based on the investigator's judgment.
During the remaining 4 weeks of the adjustable phase, the doses
established during the ﬁrst 4 weeks of the adjustable period were
kept stable. Rescue medication use was permitted as required
throughout the study.
Patients self-monitored and recorded their asthma symptoms,
limitation of daily activities, sleep disturbances and rescue
medication use in their diaries during the screening and treat-
ment periods; they also measured and recorded their peak ﬂow
daily.
The study was conducted in accordance with good clinical
practice, and the protocol was approved by each institution's ethics
committee. Parents or legal guardians were informed of study
procedures and medications, and provided written informed con-
sent before their child's enrollment. The study was registered at
http://clinicaltrials.gov with the identiﬁer: NCT01155700.
Fig. 1. Omalizumab dosing table (mg/dose). The omalizumab dose was administered by subcutaneous injection every 4 weeks (white cells) or 2 weeks (gray-shaded cells).
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The primary objective was to examine whether the geometric
mean of the serum free IgE level at week 24 was 25 ng/mL. A
reduction to this level of free IgE with omalizumab has previously
been shown to be efﬁcacious.11 Free IgE levels were measured by
enzyme-linked immunosorbent assay (ELISA) as previously
described.20,21
Secondary or exploratory efﬁcacy endpoints included change
from baseline to week 24 in: 1) mean total asthma symptom score,
which included morning, daytime and nocturnal asthma score
(0 ¼ no symptoms, 1 ¼ wheezing or tightness in chest, 3 ¼ mild
asthma attack, 6 ¼ moderate asthma attack, 9 ¼ severe asthma
attack) and cough score (0 ¼ no or 1 ¼ yes); 2) mean daily activity
score (0 ¼ not limited, 6 ¼ slightly limited, 12 ¼ almost limited,
18 ¼ completely limited); and 3) mean nocturnal sleep score
(0 ¼ sleeping well, 3 ¼ experiencing night symptoms, but able to
sleep, 6 ¼ awakening during the night sometimes, 9 ¼ having
difﬁculty sleeping). All of these were calculated according to the
standard rating scale of the Japanese Society of Allergology.22 In
addition, we assessed asthma-speciﬁc quality of life (QOL) score,
measured using the “QOL questionnaire for pediatric patients with
bronchial asthma and their parents or caregivers-short form
version 2008 (Gifu)”,23 which consists of a physical (sum of the
components of asthma attack, instability of symptoms, exercise
load) and an emotional (sum of the components of emotional
burden and proper acceptance of asthma) domain, with each
component consisting of 2 items each scored between 1 and 5
(1 ¼ severe impairment; 5 ¼ no impairment). We also measured
mean rescue medication use and the use of asthma controller
medications, as well as mean morning peak expiratory ﬂow (PEF),
FEV1 and forced expiratory ﬂow rate at 25%e75% of forced vital
capacity (FEF25e75%). We also analyzed the change from baseline in
the rates of clinically signiﬁcant asthma exacerbations (deﬁned as a
worsening of asthma symptoms that required doubling of the
maintenance ICS dose for at least 3 days and/or systemic [oral or IV]
corticosteroids), hospitalizations and ER visits due to asthma.
Safety assessments consisted of recording adverse events (AEs),
serious adverse events (SAEs), vital signs and any clinically signif-
icant changes in laboratory values, including hematology and blood
chemistry, during the 24-week treatment period. Anti-omalizumab
antibodies (IgG) were measured by ELISA as previously described21
at baseline and 16 weeks after the ﬁnal dose.
Statistical analysis
For primary analysis, the geometric mean and 95% conﬁdence
interval (CI) of the serum free IgE level at week 24 were calculated,
assuming that the serum IgE levels followed a log-normal distri-
bution. Descriptive statistics were used to summarize secondary orexploratory efﬁcacy endpoints. 95% CIs for the mean change from
baseline were calculated at each post-baseline visit. The Wilcoxon
signed-rank test for paired data was used for the rate of asthma
exacerbations, hospitalizations, and ER visits for asthma, and for
QOL to compare scores between baseline and post-treatment.
Missing values were imputed using the last observation carried
forward approach, as appropriate. Safety variables were summa-
rized descriptively.
Results
Patient baseline characteristics
Of the 51 patients screened, 38 patients (6e15 years) were
eligible for inclusion, were treated with omalizumab, and
completed the study. No patients discontinued.
A summary of the demographic and baseline characteristics are
shown in Table 1. The mean age and duration of asthma were 10.7
years and 8.4 years, respectively. 27 patients (71.1%) had allergic
sensitization to at least 4 perennial allergens. Mean ICS dose (FP
equivalent) was 469.7 mg/daydmore than double the maximum
approved dose (200 mg/day) for children in Japandand most pa-
tients (97.4%) were using LTRA and LABA, respectively. Patients had
experienced a mean of 3.1 asthma exacerbations, and 22 patients
(57.9%) had been hospitalized at least once for an asthma-related
event (mean number of hospitalizations: 1.4) in the year to study
entry. At baseline, most patients (94.7%) had limitation of daily
activities.
Efﬁcacy
The geometric mean of serum free IgE levels, which was
778.7 ng/mL at baseline, markedly decreased to 15.6 ng/mL (95% CI,
13.8e17.5) at week 24, which is below the target level of 25 ng/mL.
Mean total asthma symptom score, daily activity score and
nocturnal sleep score over time are shown in Fig. 2. Treatment with
omalizumab led to statistically signiﬁcant improvements in these
scores at week 24 compared with baseline (Table 2). The number of
patients whose scores were 0 (zero) was greatly increased at study
completion compared with baseline: for total asthma symptom
score, no patients at baseline and 11 patients (28.9%) at study
completion; 2 patients (5.3%) and 24 patients (63.2%) for daily ac-
tivity scores; and 9 patients (23.7%) and 26 patients (68.4%) for
nocturnal sleep score.
The mean (SD) number of puffs/tablets per week of asthma
rescue medicationwas 6.6 (11.17) at baseline and 2.2 (4.82) at week
24, a signiﬁcant reduction of 4.4 (95% CI: 6.9, 1.9) per week.
The rate of asthma exacerbations per patient-year over the 24-
week treatment period was statistically signiﬁcantly lower
compared with baseline (0.92 vs 2.99; p < 0.001; relative reduction
Table 2
Change from baseline in total asthma symptom score, daily activity score and
nocturnal sleep score at 24 weeks.
Baseline n ¼ 38 Week 24 n ¼ 38
Total asthma symptom scorey
Mean (SD) 21.9 (20.27) 8.3 (11.48)
Change from baseline 13.6 (19.23)
95% CI 20.0, 7.3
Daily activity scorey
Mean (SD) 21.0 (17.87) 3.9 (7.98)
Change from baseline 17.1 (17.90)
95% CI 23.0, 11.2
Nocturnal sleep scorey
Mean (SD) 9.2 (9.82) 2.8 (6.39)
Change from baseline 6.4 (11.29)
95% CI 10.1, 2.7
The higher scores represent worsening of total asthma symptom, more impaired
daily activity and nocturnal sleep, respectively.
y Scores were summarized in the value per week derived by last two weeks for
the baseline and the 24-week treatment period.
Table 1
Baseline demographic and clinical characteristics.
Omalizumab (n ¼ 38)
Age (years), mean (SD) 10.7 (2.46)
Age distribution (years), n (%)
6e9 14 (36.8)
10e15 24 (63.2)
Sex, n (%)
Male 23 (60.5)
Female 15 (39.5)
Duration of asthma (years), mean (SD) 8.4 (3.05)
Total serum IgE (IU/mL), median (range) 335.5 (33.6e1050.0)
FEV1 (% of predicted), mean (SD) 90.29 (19.336)
FEF25e75% (% of predicted), mean (SD) 76.30 (27.227)
FEV1 reversibility, mean (SD) 25.76 (24.228)
Number of asthma exacerbationsy in the
previous year, mean (SD)
3.1 (2.01)
Number of hospitalizations due to asthma in the
previous year, mean (SD)
1.4 (1.69)
Number of ER visitsz due to asthma in the
previous year, mean (SD)
0.7 (1.09)
ICS dose at baseline (mg/day, ﬂuticasone propionate equivalent)
Mean (SD) 469.7 (199.84)
Median (range) 500 (250e1000)
Asthma long-term control medications at baseline, n (%)
Leukotriene receptor antagonist 37 (97.4)
Long-acting b2-agonist 37 (97.4)
Sustained-release theophylline 23 (60.5)
Sodium cromoglycate 3 (7.9)
Oral corticosteroid 0
Proﬁle of inadequate asthma control at screening period, n (%)
Asthma symptoms every day 12 (31.6)
Night-time symptoms 2 out of the previous
14 days
25 (65.8)
Limitation of daily activities 2 out of the
previous 14 days
36 (94.7)
ER, emergency room; FEV1, forced expiratory volume in one second; ICS, inhaled
corticosteroid; SD, standard deviation.
y Asthma exacerbations requiring a doubling of the maintenance ICS dose for at
least 3 days and/or systemic (oral or IV) corticosteroids.
z If hospitalization and ER visit occurred on the same day, the event is counted as
hospitalization.
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subgroup of patients treated with high-dose ICS (500 mg/day, FP
equivalent) and two ormore controller medications comparedwith
baseline (n ¼ 20, 0.54 vs 3.05; p < 0.001).Fig. 2. Mean total asthma symptom score, daily activity score and nocturnal sleep
score over 24 weeks. Scores were summarized in the value per week derived by two-
weekly period.The rate of hospitalizations for asthma per patient-year was 0.29
over the 24-week treatment period, compared with 1.33 at base-
line, representing a reduction of 78.2% in patients receiving oma-
lizumab (p < 0.001, Fig. 3b). ER visits due to asthma over the 24
weeks were reduced by 32.4% versus baseline, but the difference
was not statistically signiﬁcant (p ¼ 0.381, Fig. 3c).
At week 24, omalizumab was associated with improvements
compared with baseline across all individual components of QOL
(Fig. 4a). Physical domain (Fig. 4b), emotional domain (Fig. 4c) and
overall (Fig. 4d) scores reached almost the upper limit of the ranges,
and showed statistically signiﬁcant improvements versus baseline
(p < 0.001).
Twenty-four weeks' treatment with omalizumab resulted in
modest improvements in lung function. Mean (SD) morning PEF
was 246.2 (72.22) L/min at baseline and 269.3 (95.59) L/min at
week 24, representing a signiﬁcant increase of 22.4 L/min
(p < 0.05), but the change from baseline in mean (SD) % predicted
morning PEF was not signiﬁcant [82.0 (21.00) % vs 86.9 (33.15) %;
difference of 5.17%]. Mean (SD) FEV1 (% predicted) values and
FEF25e75% (% predicted) values were similar at baseline and at week
24 [90.3 (19.34) % and 89.7 (23.10) % for FEV1 (% predicted); 76.3
(27.23) % and 75.8 (32.68) % for FEF25e75% (% predicted)].
At week 24, 11 patients (28.9%) had reduced the dose of any
asthma controller medication compared with the baseline
(Table 3). No patterns were noted with respect to the speciﬁc
classes of controller medications that were reduced.Safety
Overall, 36 of 38 (94.7%) patients experienced at least one AE
during the treatment period. All AEs were mild or moderate in
severity. The most common AEs (20%) were nasopharyngitis,
upper respiratory tract infection, asthma, and gastroenteritis
(Table 4).
Six patients experienced SAEs (due to hospitalization) during
the treatment period; asthma (asthma exacerbation) in ﬁve pa-
tients and urticaria in one patient. Relationship with omalizumab
was not denied in two SAEs (asthma exacerbation and urticaria),
which resolved completely with additional treatments.
No new safety concerns relating to AEs of particular clinical
interest were evident. There were no cases of anaphylactic re-
actions, malignancies, serum sickness, Churg-Strauss syndrome,
thrombocytopenia, or arterial thromboembolic events. No clinically
relevant abnormalities in laboratory tests (including platelet
Fig. 3. Changes in rate (per patient-year) of asthma exacerbations (a), hospitalizations (b) and ER visits (c) due to asthma between baseline (previous 12 months before the start of
the study plus the screening period) and 24 weeks of the treatment period. If hospitalization and ER visit occurred on the same day, the event was counted as a hospitalization. The
rates at baseline were derived as the total number of events observed during previous 12 months before the study plus the study screening period divided by the total amount of
time (in years) of the patients in this period. The rates at 24 weeks were derived as the total number of events observed during 24 weeks of treatment period divided by the total
exposure (in years) of the patients in this period.
Fig. 4. Changes in QOL scores between baseline and at 24 weeks; (a) each component (median), (b) physical domain score, (c) emotional domain score, and (d) overall score. The
boxes indicate the median, the 25th and 75th percentiles, while the extremes represent the minimum and maximum values.
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Table 3
Summary of number of patients with dose reduction or discontinuation of asthma
long-term controller medications.
Omalizumab (n ¼ 38)
Baseline n Dose reduction or
discontinuationy
at week 24 n (%)z
Any medication e 11 (28.9)
Inhaled corticosteroid 38 4 (10.5)
Leukotriene receptor antagonist 37 2 (5.4)
Long-acting b2-agonists 37 4 (10.8)
Sustained-release theophyllines 23 4 (17.4)
Sodium cromoglycate 3 1 (33.3)
y Discontinuation; Leukotriene receptor antagonist (2 patients), Long-acting b2-
agonists (3 patients), Sustained-release theophyllines (4 patients), Sodium cromo-
glycate (1 patient).
z The denominator of percentage for each asthma long-term medication is the
number of patients who used each medication at baseline.
H. Odajima et al. / Allergology International 64 (2015) 364e370 369counts) were observed. No anti-omalizumab antibodies were
detected.
Discussion
This is the ﬁrst study investigating the efﬁcacy including free IgE
suppression and safety of omalizumab in Japanese pediatric pa-
tients with severe persistent allergic asthma uncontrolled with
current standard therapy.
The primary objective was to examine whether omalizumab
decreases serum free IgE levels to less than 25 ng/ml (target level of
suppression). As a result, the geometric mean of serum free IgE
levels at week 24 was <25 ng/mL, which indicates that the current
dosing recommendations for omalizumab are appropriate for Jap-
anese pediatric patients as well as for Japanese adult and Caucasian
adult/pediatric patients.
Associated with free IgE reduction, treatment with omalizumab
led to signiﬁcant improvements in asthma control. Compared with
baseline, total asthma symptom scores, daily activity scores and
nocturnal sleep scores were markedly improved. The frequenciesTable 4
Incidence of adverse events.
Omalizumab (n ¼ 38) n (%)
Patients with any adverse event 36 (94.7)
Discontinued due to adverse event 0
Patient with serious adverse events 6 (15.8)
Asthma (asthma exacerbation) 5 (13.2)
Urticaria 1 (2.6)
Most frequent adverse eventsy
Nasopharyngitis 10 (26.3)
Upper respiratory tract infection 10 (26.3)
Asthma 8 (21.1)
Gastroenteritis 8 (21.1)
Bronchitis 5 (13.2)
Headache 5 (13.2)
Abdominal pain 4 (10.5)
Stomatitis 4 (10.5)
Urticaria 4 (10.5)
Arthralgia 3 (7.9)
Constipation 3 (7.9)
Contusion 3 (7.9)
Inﬂuenza 3 (7.9)
Injection site pain 3 (7.9)
Pyrexia 3 (7.9)
Patients with any drug-related adverse events 10 (26.3)
Most frequent drug-related adverse eventsy
Headache 4 (10.5)
Injection site pain 3 (7.9)
y Occurring in three or more patients.of asthma exacerbations and hospitalizations due to asthma were
reduced by 69.2% and 78.2%, respectively. QOL scores were also
signiﬁcantly improved, almost to the upper limits of the range. In
addition, approximately 30% of patients were able to reduce the
dose of any asthma controller medications. These consistent im-
provements including QOL were not observed in the previous
randomized controlled trial,15 but this could be explained by the
differences in the QOL questionnaire used in the studies. The
questionnaire23 used in this study assesses the QOL of both chil-
dren with asthma and their parents or caregivers, while the pe-
diatric asthma quality of life questionnaire24 used in the previous
randomized controlled trial focuses only on pediatric patients.
Because the parents (or caregivers) are deeply involved in daily
lives and therapies of their children and poorly controlled asthma
of their children impair both QOLs,25,26 this study could more
comprehensively evaluate the QOLs affected by pediatric asthma.
Although there is a limitation due to the nature of this study
(uncontrolled, non-randomized), our results support the role of
omalizumab in the management of Japanese children with severe
allergic asthma.
Regarding lung function at baseline, FEV1 (% predicted) value
was normal (90.3%), while FEF25e75% (% predicted) was diminished
(76.3%); this is consistent with the expected characteristics of se-
vere persistent asthma.27 Overall, omalizumab was associated with
little change in lung function between baseline and week 24 (PEF,
FEV1 and FEF25e75%), which was also observed in previous
studies.18,28 One possible reason might be because omalizumab
does not have a direct bronchodilator effect, it may not be effective
enough to improve lung function in severe asthma patients who
were already treated with LABA in association with high dose ICS.
In children and adolescents with severe asthma, a progressive
decline in lung function is observed over time,3,29 and asthma ex-
acerbations are thought to be associated with excess lung function
decline.5 Therefore, the longer-term effects of omalizumab on lung
function should be investigated further.
Twenty-four-week treatment with omalizumab was generally
well tolerated. No patients discontinued the study. All adverse
events were mild or moderate in severity and particular AEs of
concern for pediatric patients were not observed. Six patients
experienced SAEs, all of which resolved completely with additional
treatments. The safety proﬁle of omalizumab in the study was
comparable to that observed in the previous study,15,16 and no new
safety concerns were identiﬁed.
Several randomized studies have established omalizumab as an
effective and well-tolerated agent for use as add-on therapy in
pediatric patients with moderate to severe persistent allergic
asthma,15,16,18 but the impact of long-term treatment with omali-
zumab on the natural course of asthma is a key unanswered
question. There is some evidence that omalizumab might have a
disease-modifying effect. Nopp et al. reported thatmost of the adult
asthmatic patients who stopped omalizumab after approximately 6
years had improved or unchanged disease 3 years after stopping.30
In contrast, withdrawal of omalizumab after less than a year of
treatment resulted in a return to the pre-treatment clinical state
within months.31 Lowe et al. have suggested that IgE production in
patients with allergic asthma might be reduced during long-term
treatment with omalizumab.32 Long-term effect of omalizumab
has never been investigated yet in children. Because pediatric se-
vere asthma often persists into adult life, sometimes in a trouble-
some way,33 any disease-modifying effect of omalizumab would be
of interest.
In conclusion, the results of this study indicate that omalizumab
is effective on symptoms, exacerbations and QOL, and is well
tolerated as an add-on therapy in Japanese pediatric patients with
uncontrolled severe persistent allergic asthma.
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